

1.	Record Nr.	UNIORUON00025181
	Titolo	MANAGING health systems in developing areas : Experiences from Afghanistan / edited by Ronald W. O'Connor
	Pubbl/distr/stampa	Toronto, : Lexington Books, 1980 xvii, 314 p. ; 23 cm
	ISBN	06-690-3646-3
	Classificazione	AFG XII
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
2.	Record Nr.	UNINA9910967542303321
	Autore	Kim Sang Geon
	Titolo	AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance // Sang Geon Kim, Il Je Cho and Hee Yeon Kay
	Pubbl/distr/stampa	New York, : Nova Science Publishers, c2010
	ISBN	1-61761-457-2
	Edizione	[1st ed.]
	Descrizione fisica	1 online resource (69 p.)
	Collana	Hepatology research and clinical developments series
	Altri autori (Persone)	Choll Je KayHee Yeon
	Disciplina	616.3/6207
	Soggetti	Insulin resistance - Molecular aspects Liver - Diseases - Molecular aspects Protein kinases
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
	Note generali	Description based upon print version of record.
	Nota di bibliografia	Includes bibliographical references (p. [33]-49) and index.
	Nota di contenuto	Introduction: Insulin signaling in hepatocytes -- Clinical and preclinical drugs for the treatment of hepatic insulin resistance.
	Sommario/riassunto	Hepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly

resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver.
